Clinical trial · Observational
Vibrational Spectroscopy for Endometrial Cancer Diagnosis
Application of Vibrational Biospectroscopy as a Novel Diagnostic Tool in Endometrial Cancer
NCT05026073CI-TRIAL-00053577SPEEDunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to investigate the ability of vibrational spectroscopic techniques, Raman spectroscopy and Attenuated Total Reflection - Fourier Transform Infrared spectroscopy (ATR-FTIR), to accurately differentiate endometrial tissue, lymph nodes and blood samples with womb cancer or endometrial hyperplasia from healthy controls.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
| Endometrial Hyperplasia | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood and endometrial tissue sampling | Procedure | — | UNRESOLVED |
| Information about clinical risk factors for endometrial cancer and endometrial hyperplasia | Behavioral | — | UNRESOLVED |
| Lymph node sampling | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Group 1 Endometrial Cancer:
- description
- Women with histological diagnosis of cancer of the endometrium (any type) undergoing hysterectomy
- interventionNames
- Behavioral: Information about clinical risk factors for endometrial cancer and endometrial hyperplasia
- Procedure: Blood and endometrial tissue sampling
- Procedure: Lymph node sampling
- label
- Group 2 Endometrial Hyperplasia:
- description
- Women with histological diagnosis of endometrial hyperplasia (with or without atypia) undergoing hysterectomy
- interventionNames
- Behavioral: Information about clinical risk factors for endometrial cancer and endometrial hyperplasia
- Procedure: Blood and endometrial tissue sampling
- label
- Group 3 Controls:
- description
- Healthy women undergoing hysterectomy for a benign reason
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: 1. Endometrial cancer group: * Established histopathological diagnosis of cancer of the endometrium (any stage and subtype) * Patients must be eligible for primary staging surgery (any route, e.g. laparoscopy and laparotomy) 2. Endometrial hyperplasia group: * Established histopathological diagnosis of endometrial hyperplasia (with or without atypia) * Treatment with hysterectomy deemed necessary 3. Control group * Healthy with benign disease, non-malignancy * Undergoing hysterectomy (any route, e.g. laparoscopy and laparotomy) Exclusion Criteria: * Patient's refusal / inability to consent * Synchronous gynaecological cancer (ovary, cervix, fallopian tubes) * Previous pelvic radiotherapy * Previous hysterectomy * Undiagnosed vaginal bleeding * Previous endometrial ablation
References
Publications (0)
Data not yet available
No reference posted for this study.